Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): a prospective cohort study.
Feng S, Bibi S, Aley PK, Cappuccini F, Clutterbuck EA, Conlin K, Ebrahimi N, Eordogh A, Faust SN, Felle S, Green J, Gill H, Mujadidi Y, Oladunjoye I, Owino N, Plested E, Robinson H, Stuart A, Voysey M, Pollard AJ, Lambe T. Feng S, et al. Among authors: felle s. J Infect. 2025 Jan 16:106423. doi: 10.1016/j.jinf.2025.106423. Online ahead of print. J Infect. 2025. PMID: 39826861 Free article.
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Drury RE, Camara S, Chelysheva I, Bibi S, Sanders K, Felle S, Emary K, Phillips D, Voysey M, Ferreira DM, Klenerman P, Gilbert SC, Lambe T, Pollard AJ, O'Connor D. Drury RE, et al. Among authors: felle s. Nat Commun. 2024 Apr 22;15(1):3402. doi: 10.1038/s41467-024-47463-6. Nat Commun. 2024. PMID: 38649734 Free PMC article. Clinical Trial.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Costa Clemens SA, Marchevsky N, Kelly S, Felle S, Eldawi A, Rajasingam R, Mahmud R, Lambe T, Voysey M, Gonzalez I, Milan EP, Justino MC, Bibi S, Aley P, Clemens R, Pollard AJ. Costa Clemens SA, et al. Among authors: felle s. Hum Vaccin Immunother. 2023 Aug 1;19(2):2233400. doi: 10.1080/21645515.2023.2233400. Hum Vaccin Immunother. 2023. PMID: 37438960 Free PMC article. Clinical Trial.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Mentzer AJ, O'Connor D, Bibi S, Chelysheva I, Clutterbuck EA, Demissie T, Dinesh T, Edwards NJ, Felle S, Feng S, Flaxman AL, Karp-Tatham E, Li G, Liu X, Marchevsky N, Godfrey L, Makinson R, Bull MB, Fowler J, Alamad B, Malinauskas T, Chong AY, Sanders K, Shaw RH, Voysey M; Oxford COVID Vaccine Trial Genetics Study Team Group; Snape MD, Pollard AJ, Lambe T, Knight JC. Mentzer AJ, et al. Among authors: felle s. Nat Med. 2023 Jan;29(1):147-157. doi: 10.1038/s41591-022-02078-6. Epub 2022 Oct 13. Nat Med. 2023. PMID: 36228659 Free PMC article.
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S, Gurung M, Amatya P, Bijukchhe S, Bose AS, Carter MJ, Gautam MC, Gurung S, Hinds J, Kandasamy R, Kelly S, Khadka B, Maskey P, Mujadidi YF, O'Reilly PJ, Pokhrel B, Pradhan R, Shah GP, Shrestha S, Wahl B, O'Brien KL, Knoll MD, Murdoch DR, Kelly DF, Thorson S, Voysey M, Pollard AJ; PneumoNepal study group. Shrestha S, et al. Lancet Glob Health. 2022 Oct;10(10):e1494-e1504. doi: 10.1016/S2214-109X(22)00281-9. Lancet Glob Health. 2022. PMID: 36113533 Free article.
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19.
Kotanidis CP, Xie C, Alexander D, Rodrigues JCL, Burnham K, Mentzer A, O'Connor D, Knight J, Siddique M, Lockstone H, Thomas S, Kotronias R, Oikonomou EK, Badi I, Lyasheva M, Shirodaria C, Lumley SF, Constantinides B, Sanderson N, Rodger G, Chau KK, Lodge A, Tsakok M, Gleeson F, Adlam D, Rao P, Indrajeet D, Deshpande A, Bajaj A, Hudson BJ, Srivastava V, Farid S, Krasopoulos G, Sayeed R, Ho LP, Neubauer S, Newby DE, Channon KM, Deanfield J, Antoniades C; COMBAT Consortium; ORFAN investigators. Kotanidis CP, et al. Lancet Digit Health. 2022 Oct;4(10):e705-e716. doi: 10.1016/S2589-7500(22)00132-7. Epub 2022 Aug 26. Lancet Digit Health. 2022. PMID: 36038496 Free PMC article.
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Marchevsky NG, Li G, Aley P, Costa Clemens SA, Barrett JR, Belij-Rammerstorfer S, Bibi S, Clutterbuck E, Dold C, Felle S, Flaxman A, Folegatti P, Jenkin D, Gilbert S, Kelly S, Lambe T, Plested E, Ramasamy M, Singh N, Smith H, Taylor S, Weckx L, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group. Marchevsky NG, et al. Among authors: felle s. EBioMedicine. 2022 Jul;81:104128. doi: 10.1016/j.ebiom.2022.104128. Epub 2022 Jun 30. EBioMedicine. 2022. PMID: 35779491 Free PMC article.
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: [email protected]; COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: [email protected], et al. Cell. 2022 Mar 3;185(5):916-938.e58. doi: 10.1016/j.cell.2022.01.012. Epub 2022 Jan 21. Cell. 2022. PMID: 35216673 Free PMC article.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, Salvador N, Franco MM, de Avila Mendonça RN, Queiroz Oliveira IS, de Freitas Souza BS, Fraga M, Aley P, Bibi S, Cantrell L, Dejnirattisai W, Liu X, Mongkolsapaya J, Supasa P, Screaton GR, Lambe T, Voysey M, Pollard AJ; RHH-001 study team. Costa Clemens SA, et al. Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21. Lancet. 2022. PMID: 35074136 Free PMC article. Clinical Trial.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J, Villafana TL, Lambe T, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group. Feng S, et al. Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29. Nat Med. 2021. PMID: 34588689 Free PMC article.
20 results